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Summary Inherited susceptibility to a wide variety of neoplasias (Li-Fraumeni syndrome), has been shown in
studies of one cancer-prone family, to have an intriguing association with an aberrant c-raf-J gene and
inheritance of a radioresistant phenotype in their non-cancerous skin fibroblasts. This association together
with observations that DNA topoisomerases, when defective, can introduce errors into DNA and that these
enzymes are perturbed in vitro by serine/threonine kinases similar to rafencoded proteins, prompted investiga-
tion of DNA topoisomerase activity of the family's fibroblasts. Since radioresistance was transferred to murine
cells (NIH-3T3) when the aberrant c-raf-1 gene from this family was transfected, we also examined transfor-
mants containing this and other oncogenes. V-raflc-myc and EJ-ras transformants were examined, the former
because the family's skin fibroblasts also have 3-8-fold elevated myc expression (not apparently relevant to
radioresistance) and the latter because ras, like raf, conveys radioresistance. The family members' fibroblasts
and the three transfected murine lines, showed a similar perturbation of a spermidine and ATP-dependent
DNA catenation activity (typical of DNA topoisomerase II). There was a significant positive correlation
(r = 0.93; P = 0.0026) between the degree of activation of topoisomerase II and one measure of radioresistance
(the Dq value). Relaxation of DNA supercoiling (topoisomerase I activity and other DNA nicking enzymes)
was not abnormal. Cytotoxicity assays and evaluation of the influence of topoisomerase II inhibitors on
DNA/protein complex formation, corroborated the existence of a qualitative topoisomerase II defect in the
family's cells and transfectants. Although the contention that the qualitative topoisomerase II abnormalities
observed here may be associated with malfunction is highly speculative, these findings may be relevant to the
mechanism of oncogenesis, not only in this family, but with raf and ras type oncogenes.
DNA topoisomerases regulate the topology of DNA. Their
roles in normal cells and disease states have been widely
reviewed (Osheroff, 1989; Epstein, 1988). We have suggested
(Francis et al., 1987a,b), on the basis of several lines of
evidence, that DNA topoisomerases might be directly involv-
ed in oncogenesis. First, these enzymes can introduce errors
into DNA, particularly (but not exclusively) when perturbed
by inhibitors and activators. Their malfunction has been
implicated in mutation (Overbye et al., 1982; Pommier et al.,
1985), sister chromatid exchanges (Pommier et al., 1985;
Dillehay et al., 1987; Renault et al., 1987), illegitimate recom-
bination (Bae et al., 1988), chromosome stickiness (Renault et
al., 1987; Gaulden et al., 1987), fragmentation of DNA (Jaxel
et al., 1988) and tumour promotion (Kaneko & Horikoshi,
1987). The breadth of these observations, including mutant
studies and recombination assays where no extraneous agents
were used (Overbye et al., 1982; Bae et al., 1988), and the
range of perturbing agents eliciting errors, suggests that this
is an inherent property of these enzymes, much exacerbated
by a variety of perturbations. Second, the type II enzyme is
involved in cellular differentiation (Francis et al., 1987b).
Third, the function of both type I and II topoisomerases is
perturbed by oncogene-derived and cellular protein kinases,
including tyrosine kinases (Tse-Dinh et al., 1984) and serine/
threonine kinases (Durban et al., 1983; Rottmann et al.,
1987). The hypothetical link that perturbed topoisomerase
action provides between oncogene activation, defective differ-
entiation and a tendency to acquire further genetic changes is
provocative, since the latter two functional abnormalities are
so frequently found together in pre-neoplastic states.
In the cancer family syndrome described by Li and Frau-
meni (1969) susceptibility to many types of neoplasia is
inherited in a dominant fashion, including: sarcomas, cancers
of the breast and other tissues, neurological tumours and
both lymphoid and myeloid leukaemias. Many individuals in
six generations of a large kindred had more than one primary
cancer (Blattner et al., 1979). Thus the mechanism of onco-
genesis (although unlikely to be identical in each pedigree
(Little et al., 1987)) may be relevant to many forms of
non-familial neoplasms. Radiation resistance has been dem-
onstrated in the non cancerous skin fibroblasts from family
members (Bech-Hansen et al., 1981), but this finding is not
common to all Li-Fraumeni families (Little et al., 1987). The
ostensibly normal non-cancerous radioresistant cells were
found to have an apparent activation of the c-raf-1 gene and
a 3-8-fold elevation in the expression of c-myc (Chang et al.,
1987). The transfer of either the family's c-raf-J gene, the
genes of other serine/threonine kinases or ras, into murine
cells conveyed the radioresistant phenotype, but the myc, fes
and abl oncogenes failed to do so (Chang et al., 1987; Pirollo
et al., 1989; Sklar, 1988).
There is a potential, albeit speculative, link between muta-
bility, radiosensitivity and perturbed topoisomerase activity.
Bacterial mutants lacking a type I topoisomerase gene are
hypersensitive to DNA damage but resistant to mutation
(Sternglanz et al., 1981; Overbye et al., 1982). Chromatin
structure, particularly, but not exclusively, 'openness', is
known to influence mammalian cell DNA repair (Bohr,
1988). This may account for observations apparently linking
topoisomerase activity to repair capacity, despite failure to
detect direct involvement in repair in some systems (see
below). Since serine-threonine kinases activate topoisomer-
ases (Durban et al., 1983; Rottman et al., 1987), this partic-
ular Li-Fraumeni cancer family could conceivably be the
converse of the bacterial mutants with increased activity
and/or deranged regulation of the topoisomerases making
cells radioresistant but more prone to mutation. Suscep-
tibility to a wide range of cancers is consistent with such a
mechanism, since mutation introduced by malfunctioning
topoisomerases could affect many genomic sites.
For these reasons we have studied DNA topoisomerase
activity in non-cancerous fibroblasts from members of a Li-
Fraumeni family. Studies of NIH-3T3 transformants and a
radiosensitive ataxia-telangiectasia fibroblast line were used
to investigate the relationship between perturbation of DNA
topoisomerase, oncogene activation/expression and radio-
resistance.
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Materials and methods
Genealogy
A full genealogy of the family is not included because this is
published elsewhere (Blattner et al., 1979) and that of the
branch of the family under study was given previously
(Chang et al., 1987).
Cell lines
Nine fibroblast lines were examined. Details of their origins
are given elsewhere (Chang et al., 1987; Pirollo et al., 1989).
Five were human lines, from the proband, great uncle and
father of the cancer-prone family, an unaffected spouse and
an unrelated ataxia-telangiectasia patient (ATSBI, kindly
supplied by Dr M. Paterson to Dr E. Chang). Four were
murine NIH-3T3 lines: one containing a truncated c-raf-J
gene from a family member (Pirollo et al., 1989); a line
containing both v-raf and c-myc to simulate the co-existing
defects in the family's fibroblasts; and a line containing
activated ras (EJ). The recipient NIH-3T3 cells were used as
a control.
Cell culture
Lines were grown in Ham's F12 medium with 0.12% w/v
sodium bicarbonate, 0.27% w/v anhydrous glucose (adjusted
to pH 7.2), 2mM L-glutamine, I mM sodium pyruvate,
1000 IU m-l penicillin, 100 ig ml-' streptomycin solution
and 10% heat inactivated fetal calf serum (FCS). Experi-
ments were performed on the mouse lines at confluence and
24 h after splitting (sub-confluent with approximately 60-
80% coverage of the flask). The human lines were estimated
firstly at confluence, at 24 h post splitting (approximately
50-60% coverage), and thirdly 5 days post splitting having
been refed 24 h prior to assay (approximately 50-90% cover-
age).
Topoisomerase assays
The assay exploits the ability of topoisomerase II to catenate
(join by strand passing) supercoiled circular DNA (the plas-
mid pBR322). The supercoiled substrate plasmid is converted
to catenanes, relaxed plasmid and a small fraction is linear-
ised in this reaction. Only catenation is relatively specific for
topoisomerase II, the relaxation of supercoiling and linearisa-
tion cannot be solely attributed to type II enzyme since
topoisomerase I and any DNA nicking enzyme (e.g. endonu-
cleases) can perform this reaction. Since no topoisomerase II
assay of crude extracts can be assumed to be specific, the
characteristics of the catenation reaction were also evaluated
(see Results and Figure 2 below).
Trypinised fibroblasts were diluted in 10 ml Ham's F12
and counted using a Coulter FN. They were centrifuged at
400g for 6 min and the pellet resuspended in RPMI 1640
with 10% FCS at either 1.2 x 106 or 1.2 x 107 cells ml-',
depending on the range of extract concentrations to be
tested. The cells were recovered by centrifugation at 400g for
6 min, 200 g4 of the ice cold cytoplasmic lysis mix was added
(10 mM Tris P04 pH 6.75, 1 mM 2-mercaptoethanol, 0.1 mM
Na2 EDTA, 0.2 mM EGTA, 10% glycerol (v/v), 0.5% Triton
X-100 (v/v) 0.5% Nonidet P-40 (v/v), 1 mM phenylmethylsul-
phonylfluoride (PMSF), 1 mM dithiothreitol (DTT), 10 mM
epsilon aminocaproic acid), left on ice for 5 min, centrifuged
at 1,000g for 8 min and the supernatant reserved on ice
(cytoplasmic extract).
The pellet was washed (10 mM Tris HCl pH 7.4, 10 mM
NaCl, 1.5 mM MgCI2, 1 mM PMSF, 1 mM DTT), recentri-
fuged at 1,000g for 8 min, the supernatant discarded and the
pellet dissolved in 25j1 of nuclear lysis solution (10 mM Tris
HCI pH 7.4, 10 mM NaCl, 1.5 mM MgCl2, 1 mM PMSF,
1 mM DTT and 1 MNaCl), then left to stand for 30 min.
Polyethylene glycol 6000 (BDH) dissolved in nuclear wash
solution was added to a final concentration of 18% and the
resulting solution left for a further 15 min, then centriged at
9,000g for 15 min and the supernatant reserved on ice as the
nuclear extract. The final nuclear NaCl concentration was
0.25M.
Serial dilutions of extracts were made in the appropriate
lysis buffer with a highest concentration equivalent to 3 x 104
murine cells, 3 x 105 human cells in the cytoplasmic extract
and fourfold higher concentrations for the nuclear extracts
were mixed with 5 1 of the reaction mixture (20 mM Tris
HCI pH 8.1, 10mM MgCl2, 20 mM KCI, 0.5 mm Na3 EDTA,
30jig ml-' bovine serum albumin, 1 mM DTT, 15% glycerol
(v/v), 1OmM spermidine, 1OmM ATP and 20iLgml1' pBR
322 (BCL, supercoiled form) and incubated for 1 h at 33°C.
The amount of extract used is expressed as the equivalent
number of cells. Captothecin, the lactone form (Sigma),
10-2 M stock in dimethylsulphoxide or appropriate diluent
control was added where indicated. In selected experiments
spermidine and ATP were omitted from the reaction mixture.
The reactions were stopped by adding 2.5 p1 (0.1% SDS,
15 mM EDTA) and 2.5 p1l orange G. The products were
electrophoresed through 1% agarose gels with 1 fig ml-'
ethidium bromide in tris borate EDTA buffer pH 8.3 for 1 h
at 3 V cm-'. The various toplogical forms (catenanes,
relaxed, linearised, supercoiled) were measured by scanning
densitometry.
Cytotoxicity assays
Human fibroblasts growing in log phase were seeded at
2 x I03 cells 100 l-' in 96-well microtitre plates (Nunc). This
low cell density was chosen to preclude the possibility of
controls achieving confluence while survivors of inhibition
can continue to grow. They were incubated for 48 h at 37°C
and 5% CO2 in the presence of the DNA topoisomerase II
inhibitory agents, diluted in tissue culture medium (100 1),
VP16-213, VM26 (both kind gifts of Bristol-Myers Inc.,
Syracuse, NY, USA), mAMSA (NSC 249992 provided by the
Drug Synthesis and Chemistry Branch, NCI) and the less
inhibitory analogue of the latter oAMSA (NSC 156306) as
well as the DNA topoisomerase I inhibitor camptothecin
(Sigma). We also assessed Adriamycin (Farmitalia), which
although it inhibits topoisomerase II has additional
mechanisms of cytotoxicity including free radical generation
(Young et al., 1981). Cytosine arabinoside (Upjohn) and
thioguanine (Sigma), neither of which inhibit topoisomerase
II were also examined. All the drugs were freshly dissolved at
10-2 M in appropriate solvents, which were used as diluent
controls: the epipodophyllotoxins and amsidine derivatives in
DMSO (BDH Spectrosol grade), the thioguanine in 0.1 N
NaOH and the rest in water. The dose range tested was 10-9
to IO-5M. After 48 h, cell numbers were estimated using
essentially the method of Finlay et al. (1984) using methylene
blue staining to assess total cell mass. Robust regression
analysis using least absolute deviation (with a robust con-
stant of 1.0) was performed using a proprietary computer
algorithm (NCSS copyright of J.L. Hintze) to calculate ID
values from pooled results of quadruplicate cultures, at five
drug doses, from 2-3 experiments per drug.
Cytotoxicity assays on murine lines were performed on log
phase cells which were seeded at 0.5-1 x 103 in 96-well
microtitre plates (Nunc). They were incubated at 37°C and
5% CO2 for 16 h and then the appropriate amount of drug
or diluent was added as for the human lines. The range of
doses tested was from 10-" to 10-4M. After 4 days, viable
cell numbers were estimated by the method of Alley et al.
(1988) and analysed by similar methods to those used for the
human lines (IDm values were calculated from 12 datum
points for each of 8 drug doses).
Radiation resistance
The radiation resistance was estimated previously (Bech-
Hansen et al., 1981; Pirollo et al., 1989). The Dq values were
not previously calculated but were included in this study
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values (it should be appreciated all three parameters measure
different features of the response). The Dq value (the quasi-
threshold dose) is defined as the intersection of the extrapola-
tion of the terminal linear portion of the radiation survival
curve and the 100% survival line (Hall, 1988); the D,o value
is the radiation dose required to reduce survival to 10%. We
have re-estimated the D1O values since the earlier publication
(to ensure against changes in the cell lines) and use the most
recent estimates here, because there were some minor differ-
ences.
SDS/KCL precipitation ofDNA/protein complexes
This was performed essentially by the method of Trask et al.
(1984). Cells in exponential growth were exposed to 10-5 M
VM26 (freshly prepared as a 10-2 M stock solution dissolved
in dimethylsulphoxide) or I0- M novobiocin for 70 min.
They were trypsinised, washed in serum-containing and then
serum-free medium, then resuspended in 2 ml of serum-free
RPMI 1640 to which 0.2 ml of 10% SDS, 25 ml of buffer A
(1OmM Tris-HCI pH 7.5, 2% bovine serum albumin, 1%
SDS) and 2.5 ml of 2.5 M KCI were added sequentially. This
solution was incubated on ice for 20 min and then spun at
300g for 10 min, the supernatant discarded and the pellet
resuspended twice in a wash solution buffer B (10 mM Tris-
HCI pH 7.5, 100 mM KCI, 1 mM EDTA).
After recentrifugation (300g), the pellet was suspended in
16 ml of buffer C (1OmM Tris-HCI pH 7.5, 100 mM NaCl,
1OmM MgCl2, 1 mM EDTA) at 37C and ethanol precipit-
ated. The solution was centrifuged at 10,000g for Omin,
resuspended in TE pH 7.4 and the protein digested at 37°C
overnight with proteinase K at 400fig ml-'. The solution was
then phenol-chloroformed, ethanol precipitated and the
DNA analysed by gel electrophoresis and densitometry as
above.
Results
Both the family's fibroblast lines and the NIH-3T3 transfec-
tants have a similar perturbation of the dose response rela-
tionship for cytoplasmic catenation activity (Figure 1), with
higher thresholds, but steeper slopes and significantly
(P<0.05) elevated activity levels at high cell extract concent-
rations, with respect to control. Note there are different
scales in the a and b panels and that the logarithmic scale is
interrupted to indicate the value for no extract (0 cells).
Table I gives the statistical analyses. Like all other topoi-
somerase assays, this assay when used with crude cell extracts
cannot be assumed to be specific for topoisomerase II. We
therefore confirmed that the catenation activity (Figure 2a)
was dependent on spermidine and was reduced when exogen-
ous ATP was omitted (Figure 2b), characteristics of type II
DNA topoisomerases. Inhibition of catenation by interca-
lators cannot be used to confirm that catenation activity is
solely due to topoisomerase II because, as found by previous
workers (Zwelling et al., 1988) mAMSA incompletely inhibits
this activity. In our assay this may in part reflect the
interference of polycations on the drug/DNA/enzyme inter-
action (Pommier et al., 1989). Catenation activity was not
significantly reduced by the topoisomerase I inhibitor camp-
tothecin at 10-5 to 10-4 M (126 ± 27% and 91 ± 7% of
control respectively in three experiments). Although com-
binations of nucleases and ligase or topoisomerase I plus
nucleases could simulate catenation, the former is unlikely
because spermidine and EDTA inhibit nucleases (Krasnow
and Cozarelli, 1982) and the latter because it would be
inhibited by camptothecin.
Nuclear catenation activity was highly variable being low
or undetectable at confluence and much higher in rapidly
dividing cells. It was thus not possible (since the lines have
different growth rates) to make reliable comparisons between
lines. In 'log phase' (albeit with different growth rates)- there
was no significant difference between control nuclear extracts
(NIH-3T3 and 'spouse') and murine transfectants and
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Figure 1 (a) DNA catenation activity of fibroblast cell lines
from proband, great uncle and father of the cancer-prone family
and unaffected spouse as control. Results are means of 3-9
estimates (statistical analyses are in Table I). (b) DNA catenation
activity of transfected cell lines containing: the family's aberrant
c-raf-1; v-raf and c-myc; EJ-ras, and recipient NIH-3T3. Results
are means of 5-6 estimates (statistical analyses are given Table
I). Note different scales are used on the axes of a and b.
'family' nuclear extracts (34.9 ± 17.5% versus 26.6 ± .9.0%
and 1.4 ± 0.8% versus 6.0 ± 5.5% catenanes, per cent total
plasmid respectively). However, all but major differences
could be obscured by the differences in growth rates, since
the activities range from undetectable at confluence to much
higher levels in rapid growth. We did, however, observe that
in confluent cultures of murine cells there was residual
nuclear activity in transformants (2.5 ± 0.7%) whereas in
NIH-3T3 there was no catenation. However, it must be
emphasised that we cannot exclude differences in the
efficiency ofdensity arrest in these lines, hence this result may
not have a simple interpretation. Human confluent lines were
uninformative, having no detectable activity in tests or cont-
rols. This is in agreement with the findings of others for
untransformed fibroblasts (Davies et al., 1989).
Nuclear and cytoplasmic extracts showed no consistent
difference in relaxation of DNA supercoiling between tests
and controls (Figure 3a and b), none of the family's cells and
only two transfectants were different from controls. Note
again there are different scales in the a and b panels and that
the logarithmic scale is interrupted to indicate the value for
no extract (0 cells). Relaxation of supercoiling does not
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Figure 2 (A) Agarose gel electrophoresis of the products of
typical assays. Supercoiled plasmid (S) is converted to catenated
(C) relaxed (R) and linear (L) forms. Lane a = untreated plasmid
lanes b-d = typical reactions. Only the catenated form relates to
topoisomerase II activity whereas the formation of relaxed and
linear forms relates to it and other DNA nicking activities (see
text). (B) Representative examples of the effect of omitting sper-
midine and ATP on catenation activity. Controls contained the
standard reaction mixture and tests and controls were assayed in
triplicate. The cytoplasmic extract was not dialysed to remove
endogenous ATP. Absolute values of controls varied from 4 to
59% catenanes (% substrate plasmid).
correlate with catenation activity in this assay system, nor is
it dependent on ATP or spermidine (unpublished observa-
tions). Camptothecin 10-5 to 10- M, had a variable effect on
the ratio of supercoiled to relaxed plasmid (data not shown)
suggesting that topoisomerase I and other DNA nicking
activities make a variable contribution to DNA relaxation.
Ataxia telangiectasia (AT) contrasts with the Li-Fraumeni
syndrome in that there is a DNA repair defect associated
with a radiosensitive rather than a radioresistant phenotype
(Debenham et al., 1987). An untransformed fibroblast cell
line from an AT patient (AT5BI) was therefore compared
with the lines from the Li-Fraumeni syndrome family. In
contrast to the family's fibroblasts, AT DNA catenation
activity was reduced with respect to control, being only
detectable at the highest cell extract concentration tested
(3 x 105 cells per assay). Activity at this extract dose was not
significantly different from the spouse's cells at a tenfold
lower dose (Table I). Relaxation of supercoiling in the AT
line was not significantly different from controls (Figure 3a).
In order to confirm the apparent perturbation of the
family's DNA topoisomerase II enzyme activity, we first eval-
uated the response of fibroblasts from two family members,
the spouse and the AT patient to a panel of cytotoxic drugs.
These included those agents known to target topoisomerase I
and II, and neither enzyme. Figure 4 shows the differences in
responses of the fibroblasts to the panel. The family
members' fibroblasts (filled symbols) showed consistently a 1
to 3 orders of magnitude increase in resistance to drugs
targeting topoisomerase II (VP16, VM26 and m-AMSA).
ID25 values are shown because they demonstrated the differ-
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Figure 3 (a) Loss of supercoiling induced by cytoplasmic ex-
tracts. Means of 3-9 replicate assays are shown for the spouse,
proband, great uncle and father of the cancer-prone family and
the AT fibroblast line. (b) Loss of supercoiling induced by cyto-
plasmic extracts from the mouse fibroblast lines. Means of 5-6
replicate assays are shown for raf-3T3, raf/myc-3T3, ras-3T3 and
the recipient NIH-3T3. Note different scales are used on the axes
of a and b.
ences between the lines most clearly (this minimised the
number of points falling outside the interpolated, 10-' to
l0-' M, dose range where results cannot be ranked). With
o-AMSA there was, as anticipated for a less inhibitory struc-
tural analogue, a circa 1-2 log increase in ID25 over that
seen for m-AMSA. Adriamycin and camptothecin showed no
consistent difference between the family and non-family
members' fibroblasts. The family's cells were more sensitive
to cytosine arabinoside than the controls and less sensitive to
6-thioguanine.
Similar experiments for VM26, m-AMSA, o-AMSA and
cytosine arabinoside confirmed these results, albeit with less
marked differences, between the raf-3T3 and NIH-3T3 cells.
raf-3T3 were resistant to m-AMSA and VM26 in comparison
with NIH-3T3 (Id5o 1.6 x 10-8 M versus 7.2 x 10-9 M and
3.0 x I0-9 M versus 7.8 x 10-'° M respectively). Both raf-3T3
and NIH-3T3 were at least 2 orders of magnitude less sen-
sitive to o-AMSA than m-AMSA (ID50 1.3 x 10-6M and
3.2 x 10-6 M respectively). As with the family lines, raf-3T3
was also relatively sensitive to cytosine arabinoside (ID50
2.3 x 10-8 M versus 6.0 x 10-7 M). The raflmyc-3T3 double
transfectant did not behave like the raf-3T3 with m-AMSA,
having a greater sensitivity than control (ID50 1.8 x 10-' M),
but showed a similar resistance to VM26 (ID50 3.4 x 10-9 M).
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Table I Cytoplasmic catenation activity (catenanes % total
plasmid)
Extract concentration (cell equivalent x 105)
Line 0 0.03 0.1 0.3 1.0 3.0
Proband 0 0 0 0 5.9±3.5 17.1±2.4
(n) (6) (6) (6) (9) (3) (3)
Great uncle 0 0 0 0.9±0.6 14.4±2.6 24.7±4.9
(n) (6) (6) (6) (9) (3) (3)
Father 0 0 0 0.6±0.3 0 11.1± 2.6
(n) (6) (6) (6) (9) (3) (3)
Spouse 0 0 0.3±0.2 2.2±1.9 2.5±1.2 1.6±0.5
(n) (6) (6) (6) (9) (3) (3)
AT patient 0 0 0 0 0 3.9± 2.7
(n) (6) (6) (6) (6) (3) (3)
Control-3T3 0 8.5± 2.2 17.1 ±2.3 14.9± 2.1 - -
(n) (6) (6) (5) (5)
raf-3T3 0 0.3±0.2 13.7±2.3 26.4±2.3
(n) (6) (6) (5) (5)
raf/myc-3T3 0 2.0± 1.1 14.3±4.8 28.0±2.8
(n) (6) (6) (5) (5)
ras-3T3 0 2.5±1.7 10.1±4.0 30.9±7.1 - -
(n) (6) (5) (5) (5)
Results are mean s.e.m.
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Figure 4 Growth inhibitory concentrations for a panel of cyto-
toxic agents (for abbreviations see text). Results are ID25 values,
obtained by regression analysis of pooled experiments from pro-
band (U), great uncle (V), spouse (0) and AT line (0).
It also differed in its behaviour with cytosine arabinoside,
being more sensitive (ID50 4.8 x 10-9 M).
To substantiate further the perturbed bioactivity of the
enzyme and to investigate the basis of the abnormal response
to topoisomerase II inhibitors, we used the SDS/KCL preci-
pitation method to evaluate the formation of DNA/protein
complexes in response to two topoisomerase II inhibitors,
novobiocin and VM26 (Figure 5a). VM26, like VP16 usually
increases the amount of precipitated complexes by trapping
topoisomerase II at the stage where the enzyme is covalently
linked to DNA (Osheroff, 1989). Novobiocin, on the other
hand, usually reduces the amount of complexes and this has
been suggested to be due to it having a different inhibitory
mechanism (stimulatory effects have sometimes been observ-
ed, but these are uncommon). In contrast to NIH-3T3 which
shows this expected pattern, with more complexes in the
presence of VM26 than novobiocin, all three transformants
failed to show this pattern (Figure Sb). The raf and raf/myc
lines actually showed a reversal of the usual pattern with
higher complexes with novobiocin than with VM26 (227 ± 92
versus 48.5 8.2% diluent control respectively for the raf-
line, means s.e.m. for three independent experiments, and
122-127% versus 62.8% for the raf/myc-line). The ras trans-
formant showed a small but significant increment (137 ± 5%
diluent control, mean ± s.e.m. of three experiments) in DNA/
protein complex formation when treated with VM26 but no
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Figure 5 Influence of novobiocin and VM26 on SDS/KCl preci-
pitation of DNA/protein complexes. (a) The amount of protein-
linked DNA recovered expressed as per cent diluent control
(novobiocin = white columns; VM26 = black columns). (b) Per
cent difference VM26-novobiocin±s.e.m.
significant change when treated with novobiocin (156 +
101% diluent control, mean ± s.e.m. three experiments).
Although debated (see below), an influence of DNA topoi-
somerase on sublethal repair provides a potential link
between ras and raf activity and radioresistance. We there-
fore examined the relationship between the extent of activa-
tion of topoisomerase II and the extent of radioresistence
(assessed as Dq values). There was a significant positive
correlation (Figure 6) between the percentual increase (with
respect to appropriate control) in topoisomerase II activity at
high cell extract concentration (mean values from Table I)
and the percentual increase in Dq value. DIo values (legend to
Figure 6) and Do values (published previously) which reflect
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Figure 6 Correlation between radiation sensitivity (assessed as
Dq value) and topoisomerase catenation activity, both expressed
with respect to control (spouse for human lines and NIH-3T3 for
murine transformants). Absolute values for topoisomerase
activity were those given for the highest cell extract concentration
tested, in Table I. Equivalent D1o values were: spouse 435±3;
father 492 ±9; proband 437 ±23; great-uncle 564±35; NIH-3T3
427 ±6; raf-3T3 541 ±35; ras-3T3 5805 these were not signifi-
cantly correlated to topoisomerase activity. It is essential to
normalise with respect to the human and murine controls, since
they varied, and it thus allows pooling of human and murine
results.
different features of radiation response were not significantly
correlated with topoisomerase activity.
Discussion
Cells from three members of a cancer-prone family with the
Li-Fraumeni syndrome had a similar disturbance of dose-
response curves for cytoplasmic extract catenation activity.
The key features: higher thresholds, steeper slopes and signi-
ficantly elevated activity levels with respect to controls at
higher extract concentrations, were reproduced by transfec-
tion of the family's c-raf-1 oncogene in NIH-3T3 cells. The
perturbation of catenation activity is not consistent with
there merely being differences in the same enzymatic activity
between the cell lines, but indicates modulation of the topoi-
somerase II activity by an additional factor or factors in test
and/or control extracts. Since c-raf-J encodes a serine/threo-
nine kinase and this class of enzyme is known to activate the
topoisomerases (Durban et al., 1983; Rottmann et al., 1987),
the activated c-raf-J gene is the obvious candidate for such a
factor. Topoisomerase I activity and other DNA nicking
agents, detected by relaxation of DNA supercoiling, were not
disturbed and the contrasting results with the topoisomerase
I inhibitor camptothecin and the topoisomerase II inhibitors
in the cytotoxicity test are consistent with these enzyme assay
results.
The differential effect of the topoisomerase II inhibitors
VP-16, VM-26 and m-AMSA on the family's cells and con-
trols corroborates the evidence for a functional disturbance
of topoisomerase II (the difference between the effects of
o-AMSA and m-AMSA is consistent with their inhibitory
action in the cytotoxicity assay being related to their anti-
topoisomerase action). Although resistant to epipodophyllo-
toxins, the family's cells do not exhibit classical multi-drug
resistance since they are not significantly resistant to adria-
mycin (Ueda et al., 1987). The discrepancy between the
results for the two antimetabolities cytosine arabinoside and
6-thioguanine is obscure. Toxicity testing of the murine raf-
transfectant corroborated these results, including the sen-
sitivity to cytosine arabinonside. The double raf/myc-3T3
transfectant did not mirror this behaviour, but this could
reflect compound effects of the presence of the two oncogenes
in murine cells that do not faithfully reflect the situation in
the family's cells.
The SDS/KCL precipitation experiments (Figure 5) pro-
vide further evidence of functional abnormality of topoi-
somerase II activity and suggest abnormal interactions with
two topoisomerase II inhibitors with different mechanisms of
action, VM26 and novobiocin. This potentially provides an
explanation for the reduced sensitivity to topoisomerase II
targeting epipodophyllotoxins and intercalators. Both the
cytotoxicity data and these inhibitors studies extend the
observation of abnormal findings from cytoplasmic to
nuclear topoisomerase II, since the end-point is the formation
of complexes with, or damage of, DNA. Serine threonine
kinase-mediated phosphorylation activates topoisomerase II
(Durban et al., 1983; Rottmann et al., 1987), which at first
sight might be expected to potentiate drugs acting via this
enyzme. However, the consequences of phosphorylation vis a
vis drug/enzyme/DNA interactions are unknown.
The opposing findings for AT and the family's cells (Table
II) extend not only to radiation resistance, to the radiation
induced DNA synthesis delay (Paterson et al., 1985; Houlds-
worth & Lavin, 1980), apparent topoisomerase II activity (at
high cytoplasmic extract concentrations), but also to sen-
sitivity to topoisomerase II targeting cytotoxics, to which the
family's cells are resistant and AT cells are reportedly
hypersensitive (Henner & Blazka, 1986). This reiterates the
counter-intuitive relationship between topoisomerase II activ-
ity and drug sensitivity, but, as with the family's cells, in AT
topoisomerase II is probably not simply quantitatively chang-
ed but qualitatively abnormal with normal or even increased
protein levels (Singh & Lavin, 1989). Our finding of low
topoisomerase II activity, which corroborates observations of
Mohamed et al. (1987) and Singh et al. (1988), contrasts with
those of Smith and Makinson (1989) and Davies et al.
(1989), who found increased activity in the transformed
AT5BIVA line, also in one of two untransformed AT fibro-
blast lines, but low enzyme content in two lymphoblastoid
lines. This may reflect methodological differences in the way
various assay systems detect qualitatively abnormal enzyme.
The linkage between the phenomena illustrated in Table II is
certainly intriguing, it extends to cell line mutants (Evans et
al., 1989) and leads us to speculate that the primary lesion in
the two syndromes interferes with a cellular 'machine' that is
involved in regulating/producing these individual cell
features.
If one allowsAthat the perturbations of DNA topoisomerase
II activity (both activation and inhibition) associated with
observed enhancement in mutation, illegitimate recombination
and the introduction of other errors may be causally related,
and that an aberrant c-raf-J gene may behave like other
serine-threonine kinases which have been observed to phos-
phorylate and hence aberrantly activate DNA topoisomerase
II, this provides a readily testable hypothesis to account for
the family's cells having a higher than usual mutation rate.
We are currently examining phosphorylation status and error
rate directly. That both activation and inhibition of the
enzyme can increase error proneness, potentially reconciles
the paradox of two syndromes (AT and Li-Fraumeni) with
opposing findings for topoisomerase activity, sensitivity to
topoisomerase inhibitors and contrasting response to radia-
tion damage (Table II), but each having increased mutability.
Table II Reciprocal relationship between cell properties
Ataxia Li-Fraumeni
telangiectiasia family
Radiosensitivity increaseda reducedb
Cytoplasmic topoisomerase II decreasedc increasedd
activity
Nuclear topoisomerase II activity varied n.a.
Sensitivity to cytotoxic action of increaseda decreasedb
topoisomerase II inhibitors
aIncreased radiosensitivity in association with sensitivity to
topoisomerase II inhibitors (cleavable complex stabilising type), has
also been observed in Chinese hamster ovary cell mutants (Robson et
al., 1987; Elkind et al., 1988). bRadioresistance is associated with
resistance to topoisomerase II inhibitors in murine lymphoma lines
(Evans et al., 1989). cIn this but not all assay systems. dAt high cell
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The presence of coexisting defects in myc and raf in the
family's cells could provide a greatly increased probability for
a diverse range of tumours of many types, and could reflect
the complex nature of the pedigree with cancers in all four
ancestral lines. The raf and myc oncogenes are known to
interact synergistically in oncogenesis in experimental systems
(Rapp et al., 1988).
The influence of ras and raftransfection on radiosensitivity
and our finding that both induced an identical perturbation
of the topoisomerase II dose response curve, suggests that
this could be associated with the radioresistant phenotype
(co-ordinate findings for rafand ras may be due to ras being
upstream of raf in the same signal transduction pathway
(Rapp et al., 1988)). Support for this suggested association
comes from (1) the significant correlation observed between
the extent of topoisomerase II activation and radiation resis-
tance (Dq values); (2) the contrasting effects of serine/threo-
nine kinases (rafand mos), tyrosine kinases (fes and abl) and
myc on radioresistance (Pirollo et al., 1989), given that the
latter do not activate topoisomerases; (3) the association
between disturbed response to topoisomerase II inhibitors
and radioresistance/sensitivity observed in cell mutants (see
footnote to Table II); and (4) the association between a
radiosensitive phenotype and apparently decreased/perturbed
topoisomerase II activity found in the same studies in AT.
Given the debate concerning the evidence for a role of
topoisomerase II in DNA repair, speculation concerning a
causal relationship between the derangement of topoisomer-
ase II activity and radioresistance must be extremely ten-
tative. However, controversy mostly concerns UV-induced
excision repair and the use of novobiocin, an agent incor-
rectly assumed to be a specific inhibitor of the enzyme
(Downes & Johnson, 1988). It is premature to rule out
involvement of topoisomerase in all repair processes. First, as
mentioned above, the association in AT of radiosensitivity
and qualitatively abnormal topoisomerase II (hypersensitive
to topoisomerase II targeting cytotoxic agents (Henner &
Balzka, 1986)) is provocative. The repair defect in AT has
not yet been elucidated, but misrepair (Debenham et al.,
1987) rather than lack of ligation (Lehmann, 1982) of double
stranded DNA breaks has been implicated. Misrepair could
be a consequence of deranged topoisomerase II activity (Bae
et al., 1988). Secondly, the failure of topoisomerase II inhib-
itors (other than novobiocin which has pleotropic affects) to
inhibit repair in some systems (Downes et al., 1987; Synder et
al., 1987), is not universal (Dressier & Robinson-Hill, 1987).
In any case, such results do not rule out an indirect involve-
ment of topoisomerase II related to its influence on chroma-
tin structure, since this may not be sufficiently rapidly
affected by the inhibitors in a large enough proportion of the
genome to be revealed in short term experiments. Topoiso-
merases I and II act within and around transcriptionally
active genes (Wu et al., 1988) and such genes do have an
enhanced repair capacity (Bohr, 1988). Topoisomerase may
be involved in transitions of chromatin structure rather than
in maintaining the 'active' chromatin configuration, since the
enzyme is not found in DNAase hypersensitive, transcrip-
tionally competent sites after transcription has subsided
(Muller et al., 1987). This notion of involvement in transi-
tions is consistent with the observation that novobiocin has
its major effect in the repair of inactive rather than active
chromatin (Bohr & Hanawalt, 1986).
The association of raf and a radioresistant phenotype is
not limited to the Li-Fraumeni kindred but has been observ-
ed in head and neck cancer (Kasid et al., 1987) and with raf
and amplified myc in small cell lung carcinoma (Carney et
al., 1983; Rapp et al., 1988). Since radioresistance occurs
with other serine/threonine kinases and ras too, our finding
may have widespread implications. If radioresistance is due
to the aberrant topoisomerase this work could have direct
clinical application, since this abnormality is potentially
reversible. While the familial contribution to oncogenesis
appears to be limited (Fraumeni, 1982), the study of cancer
families and the mechanism of their inherited susceptibility to
many different forms of cancer should provide insights into
some key mechanisms of oncogenesis.
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